Sun Pharma Q4 FY26 Results: PAT Rs 2,724 Cr

Sun Pharma Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 2,724 crore for the quarter ended March 31, 2026, up 26.0% YoY compared to Rs 2,161 crore in Q4 FY25. Revenue from operations was Rs 14,612 crore, up 12.0% YoY. Results are on a Consolidated basis. Sun Pharma is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Sun Pharma Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 14,612 crore	Rs 12,959 crore	+12.0%
Gross Profit	Rs 3,179 crore	Rs 3,052 crore	+4.0%
Net Profit	2,724	2,161	+26.0%
Basis	Consolidated

Note: Sun Pharma Q4 FY26 results declared May 22, 2026. Verify from BSE/NSE audited filings before investment decisions.

Sun Pharma Q4 FY26 Performance Analysis

The Sun Pharma Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Sun Pharma operates in the Pharmaceuticals sector, which is supported by India’s GDP growth above 6.5% and domestic demand tailwinds in FY26.

Revenue of Rs 14,612 crore was up 12.0% YoY. Steady revenue momentum reflects consistent business conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Sun Pharma Q4 FY26 Results

Revenue Performance

Revenue of Rs 14,612 crore in Sun Pharma Q4 FY26 was up 12.0% YoY. The double-digit topline growth reflects strong end-market demand, market share gains, and favourable pricing conditions in the Pharmaceuticals sector. The January to March 2026 quarter is the year-end quarter, characterised by strong order execution and fiscal year-end activity across Indian corporates.

Profitability and Margin Analysis

The Sun Pharma Q4 FY26 PAT of Rs 2,724 crore up 26.0% YoY. PAT growth of 26% YoY reflects improving operational fundamentals and demand conditions in the Pharmaceuticals sector.

Sector Tailwinds and India Macro Environment

The Pharmaceuticals sector saw constructive operating conditions in Q4 FY26. India’s macroeconomic environment, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption, supported demand across sectors. The Reserve Bank of India’s accommodative liquidity stance aided credit conditions. For Sun Pharma, these macro and sectoral tailwinds provided a supportive backdrop in the January to March 2026 quarter.

FY27 Outlook

Following the business results, management commentary on FY27 revenue guidance, margin trajectory, capex plans, and demand pipeline will be the key investor focus areas. The Pharmaceuticals sector benefits from India’s long-term growth story including urbanisation, infrastructure investment, and rising middle-class consumption. Consistent growth delivery and margin improvement remain the management’s strategic priorities.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the firm